Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study

European Journal of Cancer

Volumn 47, Issue 7, 2011, Pages 1006-1012

  Schoffski P ^a,h   Taron, M ^b,l   Jimeno, J ^c   Grosso, F ^d   Sanfilipio, R ^d   Casali, P G ^d   Le Cesne, A ^e   Jones, R L ^f   Blay, J Y ^g,h,k   Poveda, A ⁱ   Maki, R G ^j   Nieto, A ^c   Tercero, J C ^c   Rosell, R ^b,l  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c PHARMAMAR S A   (Spain)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g CENTRE LÉON BÉRARD   (France)

^h EORTC DATA CENTER   (Belgium)

ⁱ Fundación Instituto Valenciano de Oncololgía   (Spain)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k Conticanet ^*  (France)

^l Pangaea Biotech   (Spain)

more..

Author keywords

DNA repair; ET 743; Sarcoma; Trabectedin; Yondelis

Indexed keywords

BRCA1 PROTEIN; DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MESSENGER RNA; NUCLEIC ACID BINDING PROTEIN; TRABECTEDIN; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP G PROTEIN;

ARTICLE; CORRELATION ANALYSIS; DNA REPAIR; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SARCOMA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRCA1 PROTEIN; DIOXOLES; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NUCLEAR PROTEINS; RECOMBINATION, GENETIC; RETROSPECTIVE STUDIES; RNA, MESSENGER; SARCOMA; TETRAHYDROISOQUINOLINES; TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 79953706562     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.01.016     Document Type: Article

References (27)

1. Rinerhart KL, Holt TG, Fregeau NL, et al. Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata. J Org Chem 1990;55:4512-5.
2. European Medicines Agency. Pre-Authorisation Evaluation of Medicines for Human Use. Committee for Medical Products for human use. Summary of positive Opinion for Yondelis. Doc. Ref. EMEA/CHMP/316962/2007. London, 19 July 2007.
3. Cassier PA, Dufresne A, Blay JY, Fayette J. Trabectedin and its potential in the treatment of soft tissue sarcoma. Ther Clin Risk Manag 2008;4(1):109-16. (Pubitemid 351460936)
4. Schöffski P, Dumez H, Wolter P, et al. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Expert Opin Pharmacother 2008;9(9):1609-18. (Pubitemid 352005920)
5. Jimeno J, Maki RG, Casali P, et al. Therapeutic impact of ET-743 (Yondelis®, Trabectidin) a new marine derived compound in Sarcoma. Curr Opin Orthop 2003;14:419-28. (Pubitemid 37414256)
6. D'Incalci M, Erba E, Damia G, et al. Unique features of the mode of action of ET-743. Oncologist 2002;7(3):210-6. Review.
7. Pommier Y, Kohlhagen G, Bailly C, et al. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996;35(41):13303-9. (Pubitemid 26349423)
8. Bonfanti M, La Valle E, Fernandez Sousa-Faro JM, et al. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des 1999;14:179-86. (Pubitemid 29428023)
9. Minuzzo M, Marchini S, Broggini M, et al. Interference of transcriptional activation by the anti-neoplastic drug ET-743. Proc Natl Acad Sci USA 2000;97:6780-4. (Pubitemid 30412791)
10. Damia G, Silvestri S, Carrasa L, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 2001;92:583-8. (Pubitemid 32319434)
11. Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin-743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001;7(8):961-6. (Pubitemid 32756435)
12. Furuta T, Ueda T, Aune G, et al. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002;62:4899-902. (Pubitemid 34984411)
13. Casado JA, Rio P, Marco E, et al. Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin. Mol Cancer Ther 2008;7(5):1309-18.
14. Van Glabbeke M, Verweij J, Judson I, Nielsen OSEORTC Soft Tissue and Bone Sarcoma Group. Progression free rate as the principal end-point for Phase II trials in soft-tissue sarcomas. Eur J Cancer 2002;38:543-9. (Pubitemid 34185394)
15. Specht K, Richter T, Müller U, et al. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 2001;158:419-29. (Pubitemid 32158605)
16. Ladanyi M, Antonescu CR, Dal Cin P. Cytogenetic and molecular genetic pathology of sotf tissue tumors. In: Sharon W. Weiss, John R. Goldblum (Eds.) Soft Tissue Tumors, Mosby Elsevier 2008, chapter 4:73-102.
17. Marco E, Garcia-Nieto R, Mendieta J, Manzanares I, Cuevas C, Gago F. A 3. (ET743)-DNA complex that both resembles an RNA-DNA hybrid and mimicks zinc finger-induced DNA structural distortions. J Med Chem 2002;45:871-80. (Pubitemid 34173937)
18. Zewail-Foote M, Hurley LH. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 1999;42:2493-7. (Pubitemid 29344290)
19. David-Cordonnier MH, Gajate C, Olmea O, et al. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin. Chem Biol 2005;12:1201-10. (Pubitemid 41628255)
20. Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 2006;66(16):8155-62. (Pubitemid 44299183)
21. Zewail-Foote M, Li VS, Kohn H, et al. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. Chem Biol 2001;8(11):1033-49. (Pubitemid 33119181)
22. Takebayashi Y, Goldwasser F, Urasaki Y, Kohlhagen G, Pommier Y. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clin Cancer Res 2001;7(1):185-91. (Pubitemid 32110222)
23. Takebayashi Y, Pourquier P, Yoshida A, Kohlhagen G, Pommier Y. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. Proc Natl Acad Sci USA Jun 22;USA 1999;96(13):7196-201. (Pubitemid 29299638)
24. Lord RVN, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in nonsmall-cell lung cancer. Clin Cancer Res 2002;8(7):2286-91. (Pubitemid 34753602)
25. Rosell R, Felip E, Taron M, et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004;10:4215s-9s.
26. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non - small-cell lung cancer. J Clin Oncol 2007;25(19):2747-54. (Pubitemid 47123183)
27. Boukovinas I, Papadaki C, Mendez P et al. Tumor BRCA1, RRM1 and RRM2 mRNA Expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS One 2008;3(11):e3695. doi:10.1371/journal.pone.0003695.